Tasly Pharmaceutical : 2016 Shareholders’ Committee, Board of Directors, and Supervisory Committee’s Meeting Held by Tasly (2016-03-31)

Mr. Xijun Yan is appointed as the Chairman of the Board, Mr. Kaijing Yan is appointed as the Executive Chairman of the Board, Mr. Xiaomeng Jiang is appointed as the Vice Chairman of the Board, and Mrs. Naifeng Wu is appointed as the President of the group.

On 27th March, the 2016 Shareholders' Committee, Board of Directors, and Supervisory Committee's meeting was successfully held at Tasly Holding Group.

The meeting deliberated and approved the Board and Supervisory Committee's motion to change the term of office. Xijun Yan, Kaijing Yan, Xiaomeng Jiang, Naifeng Wu, Zihong Du, Jianzhong Zhang, Hongnian Zhang, He Sun were elected as trustees of the Board. Mr. Xijun Yan is appointed as the Chairman of the Board, Mr. Kaijing Yan is appointed as the Executive Chairman of the Board, Mr. Xiaomeng Jiang is appointed as the Vice Chairman of the Board. Yongfeng Zheng and Jiazhi Yin are appointed as supervisors of the Supervisory Committee, Dongmei Li is appointed as employee supervisor of the 6th Supervisory Committee, Yongfeng Zheng is appointed as the Chairman of the Supervisory Committee.

The meeting approved 4 specialized committees including Strategic Committee, Audit Committee, Nominating & Payment Management Committee, and Supervision Committee, the committees are responsible for guiding Tasly's development in a all-round way, the members' list are as follow:

Strategic Committee
Chairman of the committee: Xijun Yan
Committee members: Kaijing Yan, He Sun
Audit Committee:
Chairman of the committee: Naifeng Wu
Committee members: Hongnian Zhang, Fucai Pei
Nominating & Payment Management Committee
Chairman of the committee: Xiaomeng Jiang
Committee members: Kaijing Yan, Xiuguo Du
Supervision Committee
Chairman of the committee: Xijun Yan
Committee members: Zihong Du, Jianzhong Zhang

The 6th Board of Directors appointed Mrs. Naifeng Wu as the President of the group, President Wu proposed and approved that: Mr. Jianzhong Zhang is appointed as the Executive Vice President of the group; Mr. He Sun is appointed as the Vice President and CEO of Science & Technology Innovation Group; Mr. Yonghong Zhu is appointed as Senior Assistant to the Chairman of the Board (VP level); Mr. Danyong Wu is appointed as the Vice President and CEO of Brand & Marketing Group; Mr. Zhengliang Ye is appointed as the Vice President and CEO of Production & Manufacturing Group; Mrs. Xiaoyu Liu is appointed as the Vice President and CDO of Digital Innovation Group; Mr. Qian Zhao is appointed as the Vice President and CEO of Children's Health Industry Group; Mr. Xiaobing Sun is appointed as the Chief Engineer (VP level). Mr. Fucai Pei is appointed as the Financial Officer, Chief Economic Operating Officer, and CFO (VP level); Mr. Yongsheng Wang is appointed as Secretary of the Board.

This is the first year of the decisive stage in finishing building a moderately prosperous society in all respects and a crucial year in carrying out structural reform. Tasly has established its priority in developing Great Health industry with over 20 years of development. The meeting is a significant milestone in carrying out the 13th Five-Year-Plan and achieving leaping development of great health industry.

During the meeting, the Board approved numbers of motions including 'The Report of Tasly Holding Group's 13th Five-Year Strategic Development Plan','2015 President's Work Report', '2015 Final Account Report and Profit Sharing Plans', '2016 Financial Budget Report'. The meeting further confirmed the company's goal of achieving 10 billion Yuan in both market value and business scale by 2020; the company aims to become the No.1 brand in modern biomedicine and the leading brand in great health industry; the company has also set the international goal to cultivate world class medicine.

We believe that under the plan and guidance of the new board, the senior executives will lead the whole company to work together with joint efforts. The company will follow the 13th Five-Year Strategic Development Goals and implement the 'One Five Nine Six' strategic plans to comprehensively push forward the continuous and rapid development of Tasly's Great Health industry.

Shareholders including Mr. Xijun Yan from Tianjin Dishili Investment Holding Group, Mr. Xiaomeng Jiang from Zhejiang Jianfeng Group, Mr. Jiazhi Yin from Tianjin Central Pharmaceutical Company, as well as trustees of the 5th Board of directors and supervisors of the Supervisory Committee have all attended the annual meeting.